Novo Nordisk shares closed at $62.89 in the latest trading session, marking a 1.7% decline from the previous day’s finish. This drop came as the broader market advanced, with the benchmark index rising by 0.8%. Trading volume reached 4.2 million shares, slightly above the 30-day average of 3.9 million, suggesting that investors are taking profits after a month of relative strength.

After surrendering 40% of its market value over the course of 2025, Novo Nordisk has delivered a sharp turnaround so far this year, climbing 22% year-to-date. The stock erased nearly half of last year’s decline in the first six weeks of 2026, outperforming the industry average rebound of 12% among large pharmaceutical peers. Analysts point to renewed investor confidence as the key driver behind this early recovery.

Looking ahead, Novo Nordisk is positioned to benefit from multiple product milestones. Label expansions for its flagship weight-management drug Wegovy are expected in the third quarter, potentially opening access to an additional 1.5 million patients in Europe. Regulatory approval for an oral formulation is anticipated by mid-year, while the planned launch of CagriSema in late 2026 could add an estimated $2.7 billion to annual revenues by 2028. These milestones have led six out of eight sell-side analysts to raise their 12-month revenue forecasts by an average of 4.3%.